title: Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.
abstract: BACKGROUND
  Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer.
  
  
  METHODS
  60 NSCLC patients were randomized into 3 groups in this study. 20/60 patients (group A-control group) received I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1); 20/60 (group B) received 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1); and 20/60 (group C) received all the predicted I.V. dose of carboplatin as aerosol in 3 equally divided fractions D1-3. In all patients I.V. docetaxel 100/m(2) was as well administered (D1). Lung functional tests were performed in all groups before chemotherapy in the 3rd and 6th cycles.
  
  
  RESULTS
  Group B had a statistically significant increase in survival compared to control group A [275 days (95% CI 249-300) vs. 211 (95% CI 185-236)]. In regard to lung functional tests, a statistically significant decline was observed only in FEV1 of group C in 6 months compared to the initial measurement.
  
  
  CONCLUSIONS
  Inhaled carboplatin could be given as an alternative root of pulmonary drug delivery in selected patients, but further randomized studies remain to prove whether the inhaled chemotherapy is an efficient and safe treatment modality.
authors: Pulmonary Department, Aristotle University, G Papanikolaou Hospital, Thessaloniki, Greece. pzarog@hotmail.com
authors: Paul
authors: P
authors: Zarogoulidis
authors: Ellada
authors: E
authors: Eleftheriadou
authors: Iordanis
authors: I
authors: Sapardanis
authors: Vasiliki
authors: V
authors: Zarogoulidou
authors: Helliel
authors: H
authors: Lithoxopoulou
authors: Theodoros
authors: T
authors: Kontakiotis
authors: Nikolaos
authors: N
authors: Karamanos
authors: George
authors: G
authors: Zachariadis
authors: Maria
authors: M
authors: Mabroudi
authors: Athanasios
authors: A
authors: Zisimopoulos
authors: Kostantinos
authors: K
authors: Zarogoulidis
mesh_terms: D000280:Administration, Inhalation; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D005240:Feasibility Studies; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin